TY - JOUR
T1 - FSHD type 2 and Bosma arhinia microphthalmia syndrome
AU - Mul, Karlien
AU - Lemmers, Richard J.L.F.
AU - Kriek, Marjolein
AU - Van Der Vliet, Patrick J.
AU - Van Den Boogaard, Marlinde L.
AU - Badrising, Umesh A.
AU - Graham, John M.
AU - Lin, Angela E.
AU - Brand, Harrison
AU - Moore, Steven A.
AU - Johnson, Katherine
AU - Evangelista, Teresinha
AU - Töpf, Ana
AU - Straub, Volker
AU - Kapetanovic García, Solange
AU - Sacconi, Sabrina
AU - Tawil, Rabi
AU - Tapscott, Stephen J.
AU - Voermans, Nicol C.
AU - Van Engelen, Baziel G.M.
AU - Horlings, Corinne G.C.
AU - Shaw, Natalie D.
AU - Van Der Maarel, Silvère M.
N1 - Publisher Copyright:
© 2018 American Academy of Neurology.
PY - 2018/8/7
Y1 - 2018/8/7
N2 - Objective To determine whether congenital arhinia/Bosma arhinia microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 2 seemingly unrelated disorders both caused by heterozygous pathogenic missense variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic spectrum associated with SMCHD1 dysfunction. Methods We examined and/or interviewed 14 patients with FSHD2 and 4 unaffected family members with N-terminal SMCHD1 pathogenic missense variants to identify BAMS subphenotypes. Results None of the patients with FSHD2 or family members demonstrated any congenital defects or dysmorphic features commonly found in patients with BAMS. One patient became anosmic after nasal surgery and one patient was hyposmic; one man was infertile (unknown cause) but reported normal pubertal development. Conclusion These data suggest that arhinia/BAMS and FSHD2 do not represent one phenotypic spectrum and that SMCHD1 pathogenic variants by themselves are insufficient to cause either of the 2 disorders. More likely, both arhinia/BAMS and FSHD2 are caused by complex oligogenic or multifactorial mechanisms that only partially overlap at the level of SMCHD1.
AB - Objective To determine whether congenital arhinia/Bosma arhinia microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 2 seemingly unrelated disorders both caused by heterozygous pathogenic missense variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic spectrum associated with SMCHD1 dysfunction. Methods We examined and/or interviewed 14 patients with FSHD2 and 4 unaffected family members with N-terminal SMCHD1 pathogenic missense variants to identify BAMS subphenotypes. Results None of the patients with FSHD2 or family members demonstrated any congenital defects or dysmorphic features commonly found in patients with BAMS. One patient became anosmic after nasal surgery and one patient was hyposmic; one man was infertile (unknown cause) but reported normal pubertal development. Conclusion These data suggest that arhinia/BAMS and FSHD2 do not represent one phenotypic spectrum and that SMCHD1 pathogenic variants by themselves are insufficient to cause either of the 2 disorders. More likely, both arhinia/BAMS and FSHD2 are caused by complex oligogenic or multifactorial mechanisms that only partially overlap at the level of SMCHD1.
UR - http://www.scopus.com/inward/record.url?scp=85052695211&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000005958
DO - 10.1212/WNL.0000000000005958
M3 - Article
C2 - 29980640
AN - SCOPUS:85052695211
SN - 0028-3878
VL - 91
SP - e562-e570
JO - Neurology
JF - Neurology
IS - 6
ER -